A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback